Source:http://linkedlifedata.com/resource/pubmed/id/20182022
| Subject | Predicate | Object | Context |
|---|---|---|---|
| pubmed-article:20182022 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20182022 | lifeskim:mentions | umls-concept:C0497327 | lld:lifeskim |
| pubmed-article:20182022 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:20182022 | lifeskim:mentions | umls-concept:C0338656 | lld:lifeskim |
| pubmed-article:20182022 | lifeskim:mentions | umls-concept:C0003364 | lld:lifeskim |
| pubmed-article:20182022 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:20182022 | pubmed:dateCreated | 2010-6-10 | lld:pubmed |
| pubmed-article:20182022 | pubmed:abstractText | Chronic hypertension is associated with an increased risk of both vascular dementia and Alzheimer's disease (AD). In this context, the role of anti-hypertensive therapy for the prevention and delay of cognitive decline and dementia is of central importance. Most longitudinal studies have shown a significant inverse association between anti-hypertensive therapies and dementia incidence and for some of these, particularly in AD. Seven randomized, double blind placebo-controlled trials have evaluated the benefit of antihypertensive treatments on cognition. Three of them found positive results in term of prevention of dementia (SYST-EUR) or cognitive decline (PROGRESS, HOPE). Others disclosed non-significant results (MRC, SHEP, SCOPE, HYVET-COG). This discrepancy emphasizes the difficulty to perform such trials: the follow-up has to be long enough to disclose a benefit, a large number of patients is needed for these studies, and because of ethical reasons some anti-hypertensive treatments are often prescribed in the placebo group. Results of the two more recent meta-analyses are inconsistent, possibly due to methodological issues. Antihypertensive treatments could be beneficial to cognitive function by lowering blood pressure and/or by specific neuroprotective effect. Three main antihypertensive subclasses have been associated with a beneficial effect on cognitive function beyond blood pressure reduction (calcium channel blockers, angiotensin converting enzyme inhibitor, angiotensin-AT1-receptor-blockers). Further long-term randomized trials, designed especially to assess a link between antihypertensive therapy and cognitive decline or dementia are therefore needed with cognition as the primary outcome. A low blood pressure threshold that could be deleterious for cognitive function should also be determined. | lld:pubmed |
| pubmed-article:20182022 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20182022 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20182022 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20182022 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20182022 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20182022 | pubmed:issn | 1875-8908 | lld:pubmed |
| pubmed-article:20182022 | pubmed:author | pubmed-author:HanonOlivierO | lld:pubmed |
| pubmed-article:20182022 | pubmed:author | pubmed-author:DuronEmmanuel... | lld:pubmed |
| pubmed-article:20182022 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20182022 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:20182022 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20182022 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20182022 | pubmed:pagination | 903-14 | lld:pubmed |
| pubmed-article:20182022 | pubmed:meshHeading | pubmed-meshheading:20182022... | lld:pubmed |
| pubmed-article:20182022 | pubmed:meshHeading | pubmed-meshheading:20182022... | lld:pubmed |
| pubmed-article:20182022 | pubmed:meshHeading | pubmed-meshheading:20182022... | lld:pubmed |
| pubmed-article:20182022 | pubmed:meshHeading | pubmed-meshheading:20182022... | lld:pubmed |
| pubmed-article:20182022 | pubmed:meshHeading | pubmed-meshheading:20182022... | lld:pubmed |
| pubmed-article:20182022 | pubmed:meshHeading | pubmed-meshheading:20182022... | lld:pubmed |
| pubmed-article:20182022 | pubmed:meshHeading | pubmed-meshheading:20182022... | lld:pubmed |
| pubmed-article:20182022 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20182022 | pubmed:articleTitle | Antihypertensive treatments, cognitive decline, and dementia. | lld:pubmed |
| pubmed-article:20182022 | pubmed:affiliation | Department of Geriatrics, University Paris- Descartes, Broca Hospital, AP-HP, France. emmanuelle.duron@brc.aphp.fr | lld:pubmed |
| pubmed-article:20182022 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20182022 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20182022 | lld:pubmed |